N
32.63
1.23 (3.92%)
| Previous Close | 31.40 |
| Open | 31.55 |
| Volume | 1,217,629 |
| Avg. Volume (3M) | 1,247,312 |
| Market Cap | 3,814,576,896 |
| Price / Sales | 158.40 |
| Price / Book | 5.24 |
| 52 Weeks Range | |
| Earnings Date | 5 Aug 2026 |
| Operating Margin (TTM) | -2,314.47% |
| Diluted EPS (TTM) | -1.84 |
| Quarterly Revenue Growth (YOY) | 112.60% |
| Total Debt/Equity (MRQ) | 0.05% |
| Current Ratio (MRQ) | 19.98 |
| Operating Cash Flow (TTM) | -140.43 M |
| Levered Free Cash Flow (TTM) | -99.00 M |
| Return on Assets (TTM) | -18.15% |
| Return on Equity (TTM) | -31.51% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | NewAmsterdam Pharma Company N.V | Bearish | Bullish |
AIStockmoo Score
-0.1
| Analyst Consensus | -2.0 |
| Insider Activity | NA |
| Price Volatility | 2.0 |
| Technical Moving Averages | 1.5 |
| Technical Oscillators | -2.0 |
| Average | -0.13 |
|
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Mid Growth |
| % Held by Insiders | 0.39% |
| % Held by Institutions | 111.32% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Bain Capital Life Sciences Investors, Llc | 31 Mar 2026 | 7,306,566 |
| Duquesne Family Office Llc | 31 Mar 2026 | 3,070,146 |
| Westfield Capital Management Co Lp | 31 Mar 2026 | 2,202,913 |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |